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Astract: 
Sperm DNA damage is a useful biomarker for male infertility diagnosis and prediction of 
assisted reproduction outcomes. It is associated with reduced fertilization rates, embryo 
quality and pregnancy rates, and higher rates of spontaneous miscarriage and childhood 
diseases. This review provides a synopsis of the most recent studies from each of the 
authors, all of whom have major track records in the field of sperm DNA damage in the 
clinical setting. It explores current laboratory tests and the accumulating body of 
knowledge concerning the relationship between sperm DNA damage and clinical 
outcomes. The paper proceeds to discuss the strengths, weaknesses and clinical 
applicability of current sperm DNA tests. Next, the biological significance of DNA 
damage in the male germ line is considered. Finally, as sperm DNA damage is often the 
result of oxidative stress in the male reproductive tract, the potential contribution of 
antioxidant therapy in the clinical management of this condition is discussed. DNA 
damage in human spermatozoa is an important attribute of semen quality. It should be 
part of the clinical work up and properly controlled trials addressing the effectiveness of 
antioxidant therapy should be undertaken as a matter of urgency. 
 
Introduction 
Male factor infertility is implicated in more than 40% of couples presenting for assisted 
reproduction treatment. Conventional semen analysis continues to be the only routine 
test to diagnose this condition even though it is known that such descriptive assessments 
cannot discriminate between the spermatozoa of  fertile  and  infertile  men  (Guzick et 
al., 2001). The shifting values for normality (all ‘normal’ values now lower) in the fifth 
edition of the WHO manual (World Health Organization, 2010) compared with the 
previous WHO editions may result in even less men being classified as infertile (Murray et 
al., 2012). 
 
A growing number of studies report sperm DNA damage to be useful as a diagnostic tool 
for male infertility. This criterion of sperm quality is useful as a predictor of treatment 
success as suggested by its associations at numerous points in the reproductive process 
including impaired fertilization, disrupted preimplantation embryo development, 
miscarriage and birth defects in the offspring (Bungum et al., 2012; Lewis and Aitken, 
2005; Simon et al., 2011; Zini, 2011; Zini et al., 2008). Childhood cancers have been also 
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been associated with oxidative damage to sperm DNA as a consequence of paternal 
smoking (Fraga et al., 1996; Ji et al., 1997). 
 
DNA damage in spermatozoa is primarily from oxidative stress (Aitken et al., 2010). In 
any semen sample, the vast majority of spermatozoa are abnormal (WHO, 2010). The 
spermatozoa that reflect such stress most profoundly are those morphologically 
abnormal cells that were destined for apoptosis but the process was incomplete or those 
cells that have experienced defective chromatin remodelling during spermiogenesis. 
Such defective spermatozoa are also thought to retain excess residual cytoplasm, allowing 
them to generate excessive reactive oxygen species (ROS), which, given their incomplete 
chromatin packaging, induces DNA damage (Aitken et al., 2010). 
 
DNA damage has long been the recognized universal indicator of cell lethality in toxicology 
laboratories in the pharmaceutical industry. Spermatozoa are no different. Sperm DNA 
damage is a robust indicator of cellular ill health. Now, with the aid of advances in assisted 
reproduction, fertilization can be achieved in vitro with spermatozoa that would have 
been rejected in vivo. However, by using spermatozoa with compromised DNA for 
assisted conception, the long-term health and wellbeing of children conceived by 
assisted reproduction treatment are being put at risk. As a matter of ‘best practice’, the 
DNA quality of male gametes should be tested before they are used clinically. 
 
Unfortunately, as spermatozoa have few repair mechanisms, DNA damage is commonly 
encountered in human spermatozoa, even within the fertile donor population (Simon et 
al., 2010). However, what is important clinically is the level of damage that adversely 
impacts on treatment outcomes. For any test to be useful diagnostically or prognostically, 
it must have a threshold value which provides adequate discriminatory power in the 
clinical situation. Routine semen analysis does not meet these standards (Guzick et al., 2001; 
Lefie`vre et al., 2007; reviewed by Lewis, 2007; Barratt et al., 2011), so improved assays are 
needed. 
 
Benefits and limitations of current semen tests 
Sperm numbers and quality, along with normal seminal plasma constituents, are 
crucial for fertility in vivo, so a semen analysis evaluating these parameters has long 
been the cornerstone of male infertility diagnosis. WHO provides guidance for semen 
analysis via a detailed laboratory manual and associated reference values (Cooper et al., 
2010; WHO, 2010). The current minimum standard is assessment of seminal plasma by 
volume, appearance and liquefaction of the ejaculate, and, for spermatozoa, 
measurement of concentration, motility and morphology (WHO, 2010). The recently 
revised WHO reference values are based on samples analysed according to WHO 
guidelines from 1953 men in nine countries on three continents with time to pregnancy 12 
months or less. This represents a significantly better reference population than previous 
editions of the guidelines, although it has been argued that there is still room for 
improvement (Cooper et al., 2010; Esteves et al., 2012; WHO, 1999). Analysis of semen 
samples is complicated by intersample variability caused by both technical and biological 
factors (reviewed in WHO, 2010) and WHO recommends the analysis of two or three 
samples. Consistency can be improved by implementation of quality assurance and staff 
training (Bjo¨rndahl et al., 2002) but a significant issue is that many laboratories do not 
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work to WHO guidelines (Keel et al., 2002; Penn et al., 2011; Riddell et al., 2005). It is 
recommended that semen analysis should be complemented by other clinical assessments 
(physical examination, history, endocrine and genetic investigations) as appropriate 
(Esteves et al., 2012). However, in practice this is often overlooked (Jequier, 2008). 
 
In both natural and assisted conception (with the exception of intracytoplasmic sperm 
injection (ICSI)), motility is a vital function for transit to the oocyte and penetration of 
the oocyte vestments. The strict Tygerberg criteria for assessing sperm morphology 
recommended by WHO (2010) are based on the morphology of spermatozoa capable of 
penetrating cervical mucus and binding to the zona pellucida and therefore have a basis 
in biology. There is no known link between normal head morphology and the genetic 
quality of a spermatozoon (Menkveld et al., 1990, 1991; Ryu et al., 2001; Simon et al., 
2010). This suggests that sperm DNA testing will add further information not available 
through a conventional semen analysis. Both motility and morphology measurements are 
highly sensitive to operator subjectivity/variability and further complicated by the highly 
heterogeneous nature of human sperm populations (Jørgensen et al., 1997). 
 
Although both sperm motility and morphology scores have repeatedly been found to 
positively correlate with fertilization rate (Kruger et al., 1987; Eggert-Kruse et al., 1996; 
Bonde et al.,  1998; Coetzee et al., 1998;Larsen et al., 2000; Van Waart et al., 2001; 
Ombelet et al., 2003; Haugen et al., 2006; Nallella et al., 2006; Merviel et al., 2010; 
Simon and Lewis, 2011), a detailed analysis of a large cohort of fertile and subfertile men 
by Guzick and colleagues (2001) showed an extensive overlap in the semen profiles of 
the two groups. They concluded that sperm morphology, motility and concentration 
reference values could be no more than a guide to reproductive potential, aligning with 
reports that the (1999) WHO reference values were not clinically predictive (Nallella et al., 
2006; Van der Steeg et al., 2011), although it is clearly too soon to judge whether the 
new WHO values provide a correlation with outcome. Very few (0.0041%) spermatozoa 
(Williams et al., 1993) reach the site of fertilization in vivo, This is supported by animal 
data where considerably fewer than 1% of spermatozoa reach the ampulla of the oviduct at 
the time of fertilization. Thus to expect an analysis of the gross parameters of the 
whole ejaculate to give strong discriminatory information is not realistic. There are many 
obstacles that a spermatozoon must overcome on its long journey to fertilize an oocyte 
and what is required are tests of sperm function to replace, or supplement, the surrogate 
measures currently being used (Lefie`vre et al., 2007). It is estimated that a significant 
proportion of men with unexplained infertility have a cause attributed after sperm 
genomic testing (Bungum et al., 2007). In its current form, semen analysis should be 
considered only as a means of identifying men whose chance of achieving a natural 
pregnancy is reduced. 
 
Current sperm DNA damage tests 
In recent years, the Comet, SCSA, Halo and TUNEL assays have been studied extensively 
to analyse sperm chromatin integrity. Criticisms have been made that the results from 
these tests are not equivalent. This is to be expected because, although each test 
evaluates sperm DNA quality, each may be elucidating a different aspect of DNA damage. 
Further, the parameter, DNA fragmentation index (DFI), seems to have become the 
generic term for all ‘DNA’ tests but is only applicable to the SCSA test. 
https://repository.uwc.ac.za/
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The Comet assay 
The Comet assay is a single-cell gel electrophoretic assay that quantifies broken strands 
of DNA in individual spermatozoon. Within an agarose gel, the sperm membranes are 
lysed and the DNA decondensed in a high-concentration salt solution. Disulphide bridges 
are broken down and then the spermatozoon is placed in an electrophoretic field where 
strands of charged broken DNA stream towards the cathode. As the mass of DNA fragments 
stream out from the ‘head’ of unbroken DNA they resemble a ‘comet tail’, hence the name of 
the assay. One major advantage of this assay is that only 5000 spermatozoa from a clinical 
sample are needed so it is suitable for assessment of small portions of semen left over after 
clinical use and also for oligozoospermic samples or testicular samples where only a few 
spermatozoa are available. 
 
The Comet assay is sensitive (Irvine et al., 2000; Trisini et al., 2004; Aitken and De Iuliis, 
2007) and is able to detect degrees of DNA damage in an individual spermatozoon 
rather than a percentage of damaged spermatozoa in a whole sample. The Comet assay 
also measures single- and double-strand breaks, as well as altered bases. This is useful as it 
is not yet known which types of DNA damage are most deleterious to male fertility. A 
further advantage is that, unlike some other tests which detect primarily breaks in 
protamine-associated chromatin, the Comet assay has a broader use in detecting breaks 
in both protamine- and histone-bound chromatin equally. The clinical thresholds for 
diagnosis of male infertility and prediction of success with IVF (Simon et al., 
2010,2011,2013) have now been established by studies of over 500 couples. Unlike the 
SCSA that gives a DFI value based on the number of spermatozoa in an ejaculate with 
detectable damage (subdivided into categories  of  non-detectable-,  moderate-  and  high-
damage groups), the Comet can quantify damage from 0 to 100% for each individual 
spermatozoon. The Comet is so sensitive that DNA damage is observed in every 
spermatozoon; even from fertile donors. The threshold values from the Comet assay are 
measures of the mean damage from groups of individual spermatozoon, above which 
spontaneous conception or success with IVF is less likely (Simon et al., 2010, 2013). 
Analysis of repeatability was performed using an analysis  of repeatability with the residual 
variance from the analysis of within-laboratory variance for single DNA damage 
measurements. It is 3.7% but decreases to 2.6% and 2.2% for duplicates and triplicates, 
respectively (ISO 5725:1994(E) guidelines for determination of repeatability of a 
standard measurement method; as described in Simon et al., 2013). In light of these 
results, analysis of just 50 of the 5000 spermatozoa assayed is sufficient to provide a 
measurement of DNA damage in the total sperm population with a coefficient of variation 
lower than 4%. 
 
In a recent study using the Comet assay, the effects of male infertility alone on assisted 
reproduction were evaluated by excluding all couples presenting with female factors or 
without detectable fertility problems from either partner (idiopathic infertility; Simon et 
al., 2011). This study design allowed clinical thresholds for male infertility (25%), success 
with IVF (25–50%) or the need for ICSI (>50%) to be identified. 
 
Most recently, live birth data has been reported for the first time using the Comet assay. 
Couples whose pregnancy resulted in a live birth had significantly lower sperm DNA 
fragmentation than those couples who did not achieve a live birth following IVF treatment 
https://repository.uwc.ac.za/
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(Simon et al., 2013). With the benefits of the Comet assay’s sensitivity, almost half 
previously unexplained couples now have a diagnosis in the form of sperm DNA damage 
(Simon et al., 2013). In this latest study, high levels of sperm DNA damage were also 
associated with the markedly lower live birth rates following IVF in both men and couples 
with idiopathic infertility. 
 
The usefulness of progressive sperm motility compared with DNA damage as predictive 
tools for IVF rates has also reported using the Comet assay (Simon et al., 2011). 
 
Progressive motility is the only semen parameter that correlates with sperm DNA damage. 
This may be explained as a real-time functional test of sperm vitality. However, while 
fertilization rates are directly dependent upon both sperm progressive motility and DNA 
fragmentation, the latter is a stronger test, with an odds ratio of 24.18 (95% CI 5.21–
154.51) to determine fertilization outcome compared with 4.81 (95% CI 1.89–12.65) for 
progressive motility. 
 
The sperm chromatin structure assay 
The pioneering work describing flow cytometry measurements of sperm nuclear DNA 
fragmentation was published by Evenson et al. in 1980. A significant advantage of this 
assay, the sperm chromatin structure assay (SCSA), is the simultaneous measure of two 
important fertility-dependent factors (Evenson et al., 1980): DFI and the presence of 
immature sperm nuclei with abnormal proteins and/or altered protamine/histone ratios 
(high DNA stainability, HDS; reviewed by Evenson et al., 1999, 2007). The SCSA is 
technically much less demanding than any other DNA fragmentation test and can be 
conducted on fresh or frozen–thawed semen within minutes rather than hours. It has 
only two straightforward biochemical steps: (i) treat the raw semen dilution with pH 1.2 
buffer for 30 s; and (ii) stain the spermatozoa with acridine orange, a dye that reveals 
broken DNA as red fluorescence and unbroken DNA strands as green fluorescence 
(Darzynkiewicz et al., 1975). Both the 30-s low-pH-induced opening of the DNA strands 
at sites of DNA breaks and the biochemical interaction between acridine orange and 
DNA/chromatin are precisely repeatable. This is proven by comparing cytogram scatter 
plots with 1024 channels for both X (red) and Y (green) fluorescence values in repeat 
measures of individual semen samples (Evenson et al., 1991). The 5000 dots, each 
representing single spermatozoon, were in virtually identical X, Y coordinates (±five 
channels). This scale ranges from 0–1000 and includes normal spermatozoa with no 
detectable DNA fragmentation to those with 100% DNA fragmentation. Thus, the mean 
DFI is the mean amount of DNA fragmentation for 5000 spermatozoa. The frequency 
histogram of DFI allows a precision determination of the DFI. Such observations on over 
a hundred thousand SCSA measurements negate statements such as ‘the acid treatment 
tends to denature the DNA’, as if the SCSA protocol were poorly specific. The controversy 
regarding lack of unity in the utilization and interpretation of the SCSA data is due to 
incorrect implementation of the protocol. Furthermore, publications suggesting that the 
SCSA is of little value for clinical diagnosis and prognosis have been the result of low 
numbers of patients in some studies, lack of laboratory experience with the SCSA and 
especially the lack of screening out couples where the female partner had infertility 
issues. 
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The software SCSAsoft computes the raw red versus green fluorescence data as 
red/red + green fluorescence (Evenson et al., 2002). This produces a vertical dot pattern 
for non-denatured DNA and a horizontal dot pattern for spermatozoa with fragmented 
DNA. The SCSAsoft frequency histogram of DFI allows a precision determination of DFI. 
The standard deviation of DFI is a highly sensitive measure of animal infertility 
(Ballachey et al., 1988; Didion et al., 2009)  and  genotoxicant-induced  DNA  damage  
(Sailer et al., 1997; Rubes et al., 2005). 
 
SCSA data are not correlated with the extent of free nuclear –SH groups (Evenson et 
al., 2000), freezing and thawing (Evenson et al., 1999) or sonication and gradient 
purification of sperm nuclei (Evenson et al., 1991). In a study with 182 men, the 
percentage HDS was significantly correlated with the efficiency of chromatin 
remodelling, as  measured  by  chromomycin  A3  staining  (r = 0.610, P < 0.0001). 
Interestingly, when men were given an antioxidant,  their  percentage  DFI  was  reduced  
but  HDS  was increased (Me´ne´zo et al., 2007). Pregnancies were not observed with 
HDS above 35%. Following repeated studies (Evenson et al., 1999; Spano et al., 2000; 
Evenson and Wixon, 2006a,b; Bungum et al., 2007), an internationally accepted 
statistical threshold for natural and intrauterine insemination (IUI) conception of 
rv25% DFI has been adopted. 
 
The sperm chromatin dispersion 
The sperm chromatin dispersion (SCD) or Halo test is marketed in a simple and 
inexpensive kit (Halotech DNA), available to fertility laboratories in kit form. The 
technique involves a simple differential chromatin decondensation step after which 
spermatozoa with DNA fragmentation are visually smaller than those with intact DNA, 
which appear to have a ‘halo’ around the sperm head. It takes about an hour to prepare 
slides prior to counting individual cells manually with bright-field microscopy, available in 
all fertility laboratories. Unlike all the other tests, in its most commonly used form, it 
measures the absence of damage rather than the damaged DNA in spermatozoa. The 
halo is unique with no relationship observed between it and the SCSA (Balasuriya et 
al., 2011). To date, correlations have been observed between DNA and other sperm 
parameters (Gosa´ lvez et al., 2008; Nasr-Esfahani et al., 2008) although few 
correlations between sperm DNA  damage and treatment outcomes have been 
established using this method. Some recent studies have shown no significant 
associations using ejaculated spermatozoa (n = 100, Muriel et al., 2006); n = 622, Velez 
de la Calle et al., 2008); n = 60, Yilmaz et al., 2010)) or testicular spermatozoa 
(Meseguer et al., 2009). However, in an interesting study by Meseguer et al. (2008), 
sperm DNA damage as measured by the Halo assay had a negative impact on pregnancy 
if the oocytes were from infertile women (n = 98) but not if donor oocytes (n = 112) were 
used. Using the Halo test, the dynamics of DNA fragmentation have been measured 
with time and fragmentation has been shown to increase with time after thawing 
(Gosa´ lvez et al., 2008). This is an important clinical finding, suggesting that 
immediate use of thawed spermatozoa for clinical purposes would be advisable. 
 
The TUNEL assay 
Among the different types of assays available to determine real, ‘actual’ DNA damage, the 
TdT (terminal deoxynucleotidyl transferase)-mediated dUDP nick-end labelling (TUN- 
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EL) assay is one of the oldest. It was developed by Ausubel et al. (1992) and was first 
applied to spermatozoa by Gorczyca et al. (1993). The principle of this widely used assay 
is based on the ligation of dUTP to the 30 -OH phosphate ends including blunt-ended 
and 50-recessed DNA fragments at single- and double-strand DNA breaks (Gold et al., 
1994; Nakamura et al., 1995), thus measures definite end-points, which is referred to as 
‘actual’ DNA damage. In contrast, the SCSA detects DNA damage induced by acidic 
conditions.(Alvarez, 2005; Henkel, 2007). The TUNEL and SCSA assays correlate well 
(Evenson et al., 2007), although they determine different aspects of sperm function 
(Henkel et al., 2010; Mitchell et al., 2011). 
 
Since the TUNEL assay is specific for phosphodiester-strand breaks, it is often used to 
determine apoptosis. However, this specificity has neither been demonstrated for 
spermatozoa (Manicardi et al., 1998) nor can this endpoint be used because it can also be 
reached by other mechanisms such as necrosis. Thus, by using the TUNEL assay, one 
should rather refer to this DNA damage as ‘DNA fragmentation’ than ‘apoptosis’ (Henkel 
et al., 2004; Muratori et al., 2010). 
 
Principally, the TUNEL assay can be performed using flow cytometry or microscopically 
with either fluorescent or colorimetric labels. The latter, fluorometric or colorimetric, 
should preferably be performed in cases with very low sperm count, for example in 
cases of oligozoospermia or if spermatozoa are retrieved from the epididymis or testis. 
Although not very sensitive due to technical specifics in the original protocol (Mitchell 
et al., 2011), the assay has been regarded as being precise and reproducible (Muratori et 
al., 2009). A number of different factors such as preparation, fixation and 
permeabilization of samples negatively affect its clinical application (Muratori et al., 
2010). The latter factor is due to the highly compact nature of sperm chromatin by and 
its reinforced structure in protamines due to inter- and intramolecular bonds (Balhorn et 
al., 1992; Brewer et al., 2003; Vilfan et al., 2004), which prevent TdT from directly 
accessing the DNA strand breaks. All these factors contribute to the fact that the TUNEL 
assay has not yet been standardized to the same extent as the SCSA. 
 
Only recently, solutions to these standardization problems have been found. For 
example, M540 bodies, which represent an interference in flow cytometry and contain 
apoptotic markers (Marchiani et al., 2007), were excluded and a standardized fixation 
protocol (Muratori et al., 2009) was introduced. Additionally, pretreating the samples 
with the disulphide-bridge-reducing agent dithiothreitol resulted in relaxation of the 
compact chromatin structure for TdT to access the DNA (Codrington et al., 2007). Using 
this technique, Mitchell and co-workers (2011) significantly enhanced the sensitivity of 
the TUNEL assay. Apart from its general clinical value, which has been shown repeatedly 
(Aitken et al., 2010; Henkel et al., 2004; Sharma et al., 2010), the technical 
standardization and proper clinical evaluation of the TUNEL assay are essential. Sharma 
et al. (2010) and Aitken et al. (2010) evaluated the flow cytometric TUNEL assay for 
clinical use and established reference ranges for DNA damage in patients and fertile 
donors. Nevertheless, despite the advantages of the TUNEL assay and the efforts in its 
standardization, more work remains to be done in order to eventually establish a 
robust, clinical test system to determine male infertility. 
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The value of sperm DNA adduct analysis 
Biological and environmental factors which are known to elevate DNA adduct 
formation in spermatozoa have been shown to produce marked effects on embryonic 
development and the health of the offspring (Adler, 2000; Anderson, 2001). Further 
studies have clearly indicated that DNA adduct formation in human spermatozoa has 
direct, negative impacts on fertility and is a good predictor of treatment outcome (Tyla 
et al., 2000). The current understanding of the molecular nature of the DNA damage is 
limited to mainly a handful of aryl/alkyl adducts (Witt and Bishop, 1996) and 
oxidative DNA modifications (De Iuliis et al., 2009). Nevertheless, this knowledge is 
aiding efforts to understand the underlying aetiology of sperm DNA damage. 
 
DNA fragmentation can arise through two independent mechanisms: direct enzymic 
cleavage and oxidative breakage of the backbone. In addition to these canonical 
mechanisms, DNA cleavage will also occur as a result of DNA adduct formation. 
Upon the creation of a base adduct, the glycosyl bond linking the base to the sugar 
moiety is weakened, leading to a basic site formation (Lee et al., 2009). These now-
vulnerable sections of DNA are favoured to produce strand breaks, either spontaneously 
via ribose ring opening reactions (Liu et al., 2006; Zini et al., 2008) or by targeted 
enzymic cleavage by nucleases (topoisomerase II; Cavalieri and Rogan, 2010). DNA 
fragmentation assays measure strand breaks as an end point. While this provides data on 
the level of breakage, these tests can provide little-to-no insights into the origins of 
the damage. Thus, chemical characterization of the DNA adducts present in human 
spermatozoa will provide clues to the aetiology of this DNA damage that will supplement 
the data generated by DNA fragmentation assays. 
 
The use of mass spectrometry to detect and characterize DNA adducts is well established in 
cancer research (Badouard et al., 2008; Stone et al., 2011) and is beginning to permeate 
into gamete biology (Witt and Bishop, 1996; Verhofstad et al., 2011). The measurement 
of sperm DNA modifications such as  8-hydroxy-2-deoxyguanosine  (Lee et al., 2009;  
Gharagozloo  and  Aitken,  2011;  Thomson et al., 2011; Cambi et al., 2013) and xenobiotic 
adduct formation (Zenzes, 2000)  including  benzo[a]pyrene  (Park et al., 2008), has 
been gaining much momentum of late, especially employing antibody-based analyses. 
In fact, these two lesions have been recently implicated as playing a major role in male 
infertility and the health of the offspring (Anderson, 2001; Bidmon et al., 2007; Lee et 
al., 2009). While the identification of specific xenobiotic-adducts may point toward a 
specific cause, the identification of oxidative stress markers can be common to several 
aetiologies given that oxidative stress is a major mediator of DNA damage in the male 
germ line (De Iuliis et al., 2009). Furthermore, the presence of these markers together 
with the detection of others, such as advanced glycation end products, may confirm specific 
pathologies such as diabetes (Agbaje et al., 2008). Based on the oxidative stress data, a 
pertinent body of work is being generated supporting the potential therapeutic effects of 
antioxidant supplements (Gharagozloo and Aitken, 2011; Henkel, 2012). 
 
It is clear that this fundamental comprehension of the origins of DNA damage in the 
male germ line is not only critical from a basic sperm cell biology perspective but is 
invaluable as a diagnostic for male infertility, as it can give information on the potential 
underlying causes in each case. Therefore, having now established a fundamental platform 
https://repository.uwc.ac.za/
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of information on sperm DNA strand breaks, the next step in gaining a detailed 
understanding of DNA damage to characterize the DNA adducts that created these breaks 
in the male gamete. 
 
Proxy tests for sperm DNA damage 
The major limitation of testing for sperm DNA damage is that each assay renders the 
tested spermatozoa unsuitable for clinical purpose. In an effort to overcome this problem, 
a number of non-invasive tests have been developed and their correlation with DNA 
damage assessed. These novel tests include birefringence, intracytoplasmic 
morphologically selected sperm injection (IMSI) and hyaluronic acid-selection of 
spermatozoa for ICSI. If these tests can help embryologists choose spermatozoa with low 
DNA damage for use in assisted reproduction, a major step forward in sperm selection will 
be achieved, but presently tenuous relationships are based on a few studies with very 
small numbers of cases. 
 
The implications of sperm DNA damage in the diagnosis of male 
infertility, treatment choice and the health of future generations 
Fecundity in the general population 
There is a consensus based on numerous publications that men in infertile couples have 
a higher level of sperm DNA fragmentation compared with those in the general 
population and proven fertile males. Such findings are interesting from a biological point 
of view since they point to a new, and potentially curable, cause of male infertility. Two 
independent population-based studies, one from the USA (Evenson et al., 1999) and one 
from Denmark (Spano et al., 2000), have shown that sperm DNA damage (as measured 
by DFI using SCSA) is a useful marker in the prediction of fertility in males from couples 
of unknown fertility. Thus, both studies have shown that the chance of spontaneous 
conception starts to decline at sperm DNA damage values above 20% and approaches 
zero for readings over 30–40%. This means that, although low sperm DNA damage 
(<20%) does not guarantee normal male fertility, high levels of damage are indicative of 
severely impaired male fertility. Furthermore, the SCSA data indicate that, for men who 
classified as ‘normal’ because their conventional sperm parameters are in the normal 
range, the risk of infertility starts to increase at DFI above 20% (odds ratio, OR, 5.1, 95% 
CI 1.2–23). However, this threshold drops to rv10% if the sperm concentration is below 
20 · 106/ml and/or there is an impairment of sperm motility or morphology (OR 16, 
95% CI 4.2–60; Giwercman et al., 2010). In another study (Simon et al., 2011), using the 
Comet assay, there was also a strong correlation between sperm DNA fragmentation and 
fertility status of men, with 95% of fertile donors having DNA fragmentation below 25% 
and 98% of infertile men having DNA fragmentation above 25%. The prognostic value of 
sperm DNA fragmentation in relation to infertility showed an OR for infertility of 120 
(95% CI 13–2700) in men with DNA damage above 25% (Simon et al., 2011). Thirdly, a 
comparison between male infertility patients and sperm donors using a flow cytometric 
TUNEL assay gave 19.25% as the cut-off value, with no donors but 65% patients having 
DNA damage above this level (Sharma et al., 2010). Thus, there is robust evidence from 
all the DNA fragmentation tests that the chance of spontaneous pregnancy is reduced 
when DNA damage is excessive. 
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Treatment choice 
Success rates for IUI are similar to those for spontaneous pregnancies, indicating a 
reduction in the chance of pregnancy with sperm DNA damage above 20% according to 
the SCSA (Bungum et al., 2007). If a test for oxidized bases is employed (8-hydroxy-20 -
deoxyguanosine) the results are even more sensitive, with a lower threshold value of 
11.5% (Thomson et al., 2011). 
 
In terms of IVF, a recent meta-analysis of nine IVF and 11 ICSI studies by Zini and Sigman 
(2009) showed a modestly increased pregnancy chance after  IVF (OR 1.7, 95% CI 1.3–
2.2) in cases when the proportion of DNA-damaged spermatozoa was below the 
threshold values for SCSA or TUNEL. As a result of these data, sperm DNA testing is 
now employed routinely throughout south Sweden. In further support, studies using the 
Comet assay (Simon et al., 2010, 2013; both published after Zini and Sigman’s (2009) 
meta-analysis) showed an OR of 76 (95% CI 8.7–1700) for clinical pregnancy if the 
mean DNA fragmentation per spermatozoon was below 52% (Simon et al., 2011). The 
latest study using the Comet assay showed that couples with low levels of sperm DNA 
fragmentation (<25%) had a live birth rate of 33% following IVF treatment. In contrast, 
couples with high levels of sperm DNA fragmentation (>50%) had a much lower live birth 
rate of 13% following IVF treatment of couples with idiopathic infertility, 39% have high 
sperm DNA damage. Sperm DNA damage was also associated with lower live birth rates 
following IVF in couples with idiopathic infertility than couples with detectable causes. 
 
Sperm DNA damage has not been found to be predictive for ICSI treatment (Zini, 2011) 
except for one exception (Bungum et al., 2007). However, in this study, couples were not 
randomized for IVF or ICSI so the impact of other factors contributing to the choice of 
treatment cannot be excluded. A number of reasons have been put forward to explain the 
finding that poor sperm DNA does not appear to impact adversely on ICSI outcomes. 
Firstly, unlike IVF, up to 30% of women (with subfertile partners) having ICSI have no 
detectable problems. They may be fertile and their oocytes may have more capacity to 
repair DNA damage even if the injected spermatozoon is of poor quality. This is 
supported by the findings of Meseguer et al. (2011) where high-quality oocytes from 
donors offset the negative impact of sperm DNA damage on pregnancy. 
 
Secondly, a recent major study from Dumoulin et al. (2010) shows that even the 
birthweight of IVF babies can be markedly influenced by minor differences in culture 
conditions. In contrast to IVF, ICSI spermatozoa are injected into the optimal 
environment of the ooplasm within a few hours of ejaculation. This may protect 
them from laboratory-induced damage. 
 
Thirdly, it is well documented that spermatozoa from up to 40% of infertile men have 
high levels of ROS (Aitken et al., 2012; Henkel, 2011) and their antioxidant content is 
also significantly lower than fertile men (Lewis et al., 1995). During the IVF process, 
oocytes can be exposed to an overnight oxidative assault from 0.5 million spermatozoa 
releasing ROS. This may well impair the oocyte’s functional ability, including its capacity 
to repair sperm DNA fragmentation post fertilization. 
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Finally, as mentioned above, evidence is emerging that embryos with high sperm DNA 
damage are associated with early pregnancy loss (reviewed by Zini et al., 2008; using 11 
studies composed of 808 IVF and 741 ICSI cycles) so ICSI success rates are sometimes 
affected adversely by sperm DNA damage but at a later stage. In fact, high levels of sperm 
DNA damage are associated with increased risk of pregnancy loss (OR 2.5, 95% CI 1.5–
4.0), regardless of the in-vitro technique applied (reviewed by Robinson et al., 2012). 
 
Early pregnancy loss, whether following spontaneous or assisted conception is another 
form of infertility, and one for which we need to develop an appropriate patient pathway. 
 
Implications for future generations’ health 
Importantly, compounds that induce oxidative stress in the male germ line such as iron 
dextran have also been shown to generate positive results in dominant lethal assays 
(Doreswamy and Muralidhara, 2005). The importance of oxidative stress in the aetiology 
of the dominant lethal effect is also emphasized by the fact that polyphenolic antioxidants 
can reverse the dominant lethal impact of benzo[a]pyrene (Shukla and Taneja, 2001). 
Similarly, enhancing the concentration of reduced glutathione in the male reproductive 
tract following treatment with N-acetylcysteine was found to reduce the dominant 
lethal effects observed with ethyl methanesulphonate, while glutathione depletion with 
phorone had the opposite effect (Gandy et al., 1992). The literature on male-mediated 
toxicity in animals, and the dominant lethal assay in particular, is extensive and 
demonstrates beyond doubt that the induction of DNA damage in the male germ line can 
induce miscarriage or, if the pregnancy carries to term, morbidity in the offspring, 
including an enhanced susceptibility to tumour formation. 
 
To set this fundamental point beyond doubt, Ferna´ndez-Gonzalez et al. (2008) 
performed ICSI with mouse spermatozoa that had their DNA damaged by a freeze–
thaw cycle in the absence of cryoprotectant. Fertilization with such damaged 
spermatozoa allowed embryonic development to proceed to term but at a reduced rate 
compared with control animals. Furthermore, the offspring that were generated in this 
study following ICSI showed reduced longevity, increased behavioural abnormalities and 
a significant rise in the incidence of pathologies, including the age-dependent 
appearance of solid tumours (Ferna´ndez-Gonzalez et al., 2008). 
 
These animal studies provide experimental support for the correlative associations that 
have been observed clinically between DNA damage in human spermatozoa and morbidity 
in children. One paradigm that perfectly illustrates the power of these associations is 
paternal ageing. Thus, numerous studies demonstrate that paternal age is associated 
with a high incidence of DNA damage in human spermatozoa (Schmid et al., 2007; Singh 
et al., 2003; Varshini et al., 2012) as well as an increase in the mutational load 
subsequently carried by the offspring (Kong et al., 2012). Whether there is a mechanistic 
link between DNA damage in the germ line on the one hand and increased mutation 
rates in the embryo on the other is a critical issue that remains unresolved. It is 
possible that advanced paternal age is associated with an increased mutation rate in 
the spermatogonial stem cell population as a consequence of replication errors that are 
completely independent of any DNA damage seen in the spermatozoa. Alternatively, the 
DNA damage recorded in the spermatozoa of older men may be directly responsible for 
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the age-dependent increase in mutational load seen in the embryo, as a result of aberrant 
DNA repair in the oocyte prior to the initiation of S-phase of the first mitotic division 
(Aitken et al., 2004). Whatever the nature the genetic damage present in the 
spermatozoon as a consequence of paternal age its appearance is correlated with an 
increase in neurological conditions in the offspring such as epilepsy, spontaneous 
schizophrenia, autism and bipolar disease (Sipos et al., 2004; Reichenberg et al., 
2006; Aitken and De Iuliis, 2007; Frans et al., 2008). DNA lesions in the spermatozoa of 
ageing fathers are also associated with an increased risk of cancer in the offspring 
(Hemminki et al., 1999; Johnson et al., 2011), birth defects (Green et al., 2010) and the 
appearance of dominant genetic mutations including achondroplasia and Apert’s 
syndrome (Crow, 2000). 
 
A second paradigm that shows the same relationship between DNA damage in the 
spermatozoa and a significantly increased risk of morbidity in the offspring is smoking. 
Paternal smoking creates oxidative stress in the ejaculate and significantly enhanced 
levels of oxidative DNA damage in the spermatozoa (Fraga et al., 1996). A number of 
independent studies have indicated that this genetic damage to the spermatozoa is, in 
turn, associated with significantly increased levels of cancer in the offspring (Ji et al., 
1997; Lee et al., 2009). 
 
A third situation in which DNA damage in the spermatozoa is associated with defects in 
the offspring is assisted reproduction treatment. The detrimental effect of assisted 
conception on the health and wellbeing of the progeny has been conclusively 
demonstrated in a recent meta-analysis (Wen et al., 2012). In this review of the existing 
literature, no difference was found between the risks associated with IVF and ICSI; 
however, a recent analysis of pregnancies in South Australia revealed a significantly 
enhanced chance of birth defects in ICSI compared with IVF children (Davies et al., 
2012). Interestingly, this difference was not observed with cryostored embryos, suggesting 
that the stresses associated with embryo freezing might selectively eliminate any defective 
embryos generated as a result of the ICSI procedure. In light of these results, routine 
cryostorage of ICSI embryos might be considered in cases where DNA damage in the 
father’s spermatozoa is high and a potential risk to the normality of embryonic 
development is therefore evident. 
 
Finally, because the three factors known to be associated with DNA damage in human 
spermatozoa (ageing, smoking and infertility) are also associated with the formation of 
oxidative DNA adducts in the germ line, these data suggest that oxidative stress is a 
critical trigger for paternally mediated impacts on development. The implications of this 
rationale are 2-fold. Firstly, if this is the case, then any factor capable of causing oxidative 
stress in the male reproductive tract is capable of influencing the health and wellbeing of 
the next generation. The list of such factors is very extensive and, in addition to age 
and smoking, includes alcohol consumption, exposure to radio-frequency 
electromagnetic radiation, chemotherapy, diabetes, heat, testicular torsion, oestrogenic 
steroids, anti-retroviral drugs, anti-epileptics, phthalate esters, heavy metals, 
acrylamide, arsenic, pesticides, herbicides, paracetamol, hypobaric hypoxia, cryostorage 
and indeed idiopathic infertility, among others (Mathur and D‘Cruz, 2011). Given the 
extensive nature of this list, it is not surprising that oxidative DNA damage in human 
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spermatozoa is such a widespread phenomenon (Aitken et al., 2010, 2012). The 
implications of such damage in terms of the incidence of disease in the offspring is 
therefore potentially immense. Secondly, if oxidative stress is involved in the aetiology of 
DNA damage then antioxidants should be part of the cure (Greco et al., 2005). 
 
The potential of antioxidant therapy 
Excess ROS chemically modify cellular components such as proteins, lipids, RNA and 
DNA molecules, thus impairing normal cell function. This is true for all cell types. Sperm 
cells are particularly vulnerable to oxidative attack for three reasons: (i) their plasma 
membrane is largely composed of polyunsaturated fatty acids such as docosahexaenoic 
acid, which, with six double bonds per molecule, creates an ‘electron sink’ rendering it 
highly susceptible to oxidation and other chemical modifications (Jones et al., 1978, 1979); 
(ii) spermatozoa have inherent deficiencies in intracellular antioxidant enzyme 
protection; and (iii) unlike most cell types, spermatozoa have a limited capacity for DNA 
damage detection and repair. Chronic oxidative stress in the male reproductive tract is 
therefore potentially detrimental to sperm health compromising motility, membrane 
fusion events with the oocyte and, most critically, the integrity of the DNA they 
transport. Nonetheless, depending on factors such as the nature, extent and location of the 
DNA damage, spermatozoa with such lesions can still fertilize oocytes and generate 
pregnancies. Such pregnancies will carry an elevated risk of miscarriage and may lead to 
embryonic DNA mutations with deleterious consequences for the health of the offspring. 
It is therefore prudent to include tests that measure sperm DNA damage as part of the 
patients’ routine semen analysis. Patients diagnosed with moderate-to-severe oxidative 
DNA damage will be guided towards a more informed decision regarding the most 
appropriate treatment. For example, patients may be advised to skip IUI treatments 
altogether in favour of IVF or ICSI since IUI success rates are very poor for patients with 
sperm DNA damage. Moreover, the physician may recommend the use of testicular 
spermatozoa or high-magnification ICSI as alternative procedures. In all cases, patients 
with oxidative DNA damage should be encouraged to consider a simple course of 
antioxidants as a first-line therapy prior to undertaking any form of assisted reproduction 
treatment. The use of antioxidants in ameliorating sperm oxidative stress has been the 
subject of some 20 clinical trials over the last decade, summarized in a recent review 
paper (Gharagozloo and Aitken, 2011). Although, most of these trials have serious 
shortcomings, the results unanimously and consistently show a reduction of sperm 
oxidative stress with a diverse array of antioxidants. In some cases, the reported 
improvement is accompanied by correlations with one or more secondary clinical 
outcomes such as pregnancy. These studies do not delineate which antioxidant or 
combination of antioxidants offers the best protection against oxidative stress and there 
is no clear consensus regarding the doses of the antioxidants that should be 
administered. Future research and clinical studies should address these issues as a 
matter of urgency. For now, based on current studies and theoretical considerations, we 
offer the following opinion. Since oxidative stress is not a localized phenomenon in cells 
or in tissues and is caused by vastly different oxidants, it is reasonable to assume that a 
combination of antioxidants targeting the male reproductive tract with the appropriate 
oral bioavailability will tender a better protection than any single antioxidant. It should 
also be noted that the complexities involved in the identification of such a formulation is 
never a trivial one as there are no ‘hard and fast’ rules in developing such a formula. 
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While awaiting the development of efficacious formulations backed up by quality human 
clinical data, physicians should consider the use of one or more antioxidant(s) reported in 
recent review papers (Zini et al., 2009; Lanzafame et al., 2009; Ross et al., 2010; 
Gharagozloo and Aitken, 2011; Showell et al., 2011). Fortunately, there is little or no 
concern over the safety of these natural antioxidants with the following caveats. High 
doses and long durations of administration as well as the use of synthetic or chemically 
modified versions of antioxidants should be avoided. For example, the long-term use of 
synthetic esterified racemic vitamin E at 400 IU/d in the large cancer prevention SELECT 
clinical trials shows a significant rise in prostate cancer among healthy men (Klein et 
al., 2011). Additionally, antioxidants with no known benefit to reproductive health 
should not be considered. Physicians or IVF specialists should also avoid the use of 
arbitrary antioxidant formulations where little evidence concerning their safety and 
efficacy is reported. Some formulations may combine a large number of antioxidants 
with aggressive doses, raising the possibility of ‘reductive stress’ (O’Flaherty et al., 2005) 
by potentially depleting the physiological concentration s of ROS known to be critical for 
normal sperm function. It is also important to note that, according to recently 
published data, 40% of men seeking fertility treatment are fertile and devoid of sperm 
oxidative DNA damage (Cohen-Bacrie et al., 2009). These men do not require anti- 
oxidant treatment, which may in fact lower their fertility potential. For example, 
administering selenium to fertile men is known to reduce the number of motile 
spermatozoa possibly through modifying thyroid hormone metabolism (Hawkes and 
Turek, 2001). Similarly, in high doses, vitamin C is reported to reduce the interchain 
disulphide bridges in protamines opening the cysteine net and subsequently promoting 
DNA decondensation in spermatozoa (Donnelly et al., 1999; Me´ne´zo et al., 2007; 
Giustarini et al., 2008). 
 
Thus, based on such overwhelming considerations and as a matter of ‘best practice’, the 
current status quo governing male fertility treatment should change to include tests of 
sperm DNA quality as part of the routine semen analysis. To enhance fertility potential, 
lower the risk of miscarriage and reduce sporadic embryonic DNA mutations, patients 
tested positive for sperm DNA damage should be treated with one or more antioxidants 
for the duration of spermato-genesis. This approach will lead to improvement of 
patients’ sperm DNA quality prior to undertaking  any form of fertility treatment by 
assisted reproduction treatment. 
 
Conclusion 
The large body of literature informs those working in human fertility of the importance of 
assessing DNA damage in human spermatozoa, in terms of effectiveness of treatment and 
the health of offspring conceived using this technology. It is an important element of 
semen quality: useful in the diagnostic workup of the male and also as an additional 
indicator of assisted reproduction treatment success. Well-designed and powered 
clinical trials should be undertaken to address the effectiveness of antioxidant therapy as 
a matter of urgency. 
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